Viking Therapeutics, Inc. VKTX
Composite 37/100; the shares have moved about 53% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 6/100 — a strong mark against it.
Balance-sheet strength ranks 88/100 — a strong point in its favour. Momentum ranks 51/100 — a slight point in its favour.
Quality ranks 6/100 — a strong mark against it. Valuation ranks 9/100 — a strong mark against it.
What the company does Viking Therapeutics is a clinical-stage biotech developing oral therapies for metabolic and endocrine disorders. Its lead asset, VK2809, targets non-alcoholic steatohepatitis (NASH) via thyroid hormone receptor beta agonism. Other programs include VK5211 (post-hip fracture recovery), VK0612 (metabolic disorders), VK2735 (GLP-1/glucagon dual agonist), and VK0214 for X-linked adrenoleukodystrophy.
Key financials VKTX shows no revenue (0.0% growth) and negative profitability (ROE -70%, ROA -42.5%). Margins are flat (Gross/Operating/Net 0.0%), with a current ratio of 5.72x. Valuation metrics are distorted (P/E 0.00, EV/EBITDA -71.64, P/B 8.05), reflecting pre-revenue status.
Stock health Momentum is mixed: +5.68% (3m), +8.88% (6m), but -23.27% below its 52-week high. RSI(14) at 39.80 suggests oversold conditions. Sideravia scores it "Poor quality, attractively valued" (Overall 51.8), with Strength at 96.1 and Valuation at 71.4.
Price vs fair value The stock trades at a **discount of 180.88%** versus the analyst 12-month target of 93.00. - Analysts cite potential as a pharma takeover target post-Crinetics’ $10B deal (Motley Fool). - Q2 earnings beat estimates despite rising R&D costs (Zacks). - Obesity pipeline progress highlighted in earnings calls (GuruFocus, MarketBeat). - Stock lagged GLP-1 peers in July but CEO touts differentiated obesity drug (Stocktwits).
Looking forward VKTX’s valuation hinges on Phase IIb NASH (VK2809) and obesity (VK2735) data. Success could unlock significant upside, but binary clinical outcomes and no near-term revenue keep risk elevated. Monitor enrollment and interim readouts for catalysts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.